Stoke Therapeutics (NASDAQ:STOK) Stock Rating Reaffirmed by Wedbush

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “outperform” rating restated by Wedbush in a research note issued to investors on Thursday, Benzinga reports. They presently have a $17.00 price objective on the stock. Wedbush’s price target points to a potential upside of 19.30% from the company’s previous close.

Other equities research analysts have also issued reports about the company. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Friday, June 28th. TD Cowen raised Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 26th. HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, May 7th. Canaccord Genuity Group reduced their price target on Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, May 7th. Finally, JPMorgan Chase & Co. boosted their price target on Stoke Therapeutics from $6.00 to $13.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 26th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $20.57.

Stoke Therapeutics Price Performance

Shares of STOK stock opened at $14.25 on Thursday. Stoke Therapeutics has a 52-week low of $3.35 and a 52-week high of $17.58. The stock has a 50 day moving average price of $14.15 and a 200 day moving average price of $9.95.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Monday, May 6th. The company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.03. The firm had revenue of $4.22 million for the quarter, compared to the consensus estimate of $3.33 million. On average, equities analysts anticipate that Stoke Therapeutics will post -2.3 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Skorpios Trust sold 3,600,000 shares of the business’s stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the transaction, the insider now directly owns 10,843,681 shares in the company, valued at approximately $125,786,699.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, insider Barry Ticho sold 10,000 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $13.75, for a total transaction of $137,500.00. Following the transaction, the insider now directly owns 2,485 shares in the company, valued at approximately $34,168.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Skorpios Trust sold 3,600,000 shares of the business’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total value of $41,760,000.00. Following the sale, the insider now owns 10,843,681 shares in the company, valued at approximately $125,786,699.60. The disclosure for this sale can be found here. 11.30% of the stock is owned by company insiders.

Institutional Trading of Stoke Therapeutics

Large investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio purchased a new stake in Stoke Therapeutics during the 3rd quarter valued at about $64,000. State Board of Administration of Florida Retirement System purchased a new stake in Stoke Therapeutics during the 1st quarter valued at about $141,000. BNP Paribas Financial Markets grew its stake in Stoke Therapeutics by 86.2% during the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after purchasing an additional 6,636 shares during the last quarter. Chase Investment Counsel Corp purchased a new stake in Stoke Therapeutics during the 1st quarter valued at about $279,000. Finally, Los Angeles Capital Management LLC grew its stake in Stoke Therapeutics by 30.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 62,257 shares of the company’s stock valued at $327,000 after purchasing an additional 14,510 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.